US FDA grants Breakthrough Therapy Designation to Pfizer’s Respiratory Syncytial Virus vaccine…
The decision is primarily informed by the positive results of a proof-of-concept, phase IIa study evaluating the safety,…
Recover your password.
A password will be e-mailed to you.